BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by UBS Group

BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by analysts at UBS Group to a “strong-buy” rating in a note issued to investors on Wednesday, Zacks reports.

Several other research firms also recently weighed in on BMRN. Oppenheimer increased their price objective on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, August 7th. HC Wainwright reaffirmed a “neutral” rating and issued a $60.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, September 10th. Weiss Ratings downgraded shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 18th. Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Raymond James Financial upgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 price target for the company in a research note on Monday, October 12th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $88.87.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock traded down $1.37 on Wednesday, hitting $54.68. The stock had a trading volume of 2,627,811 shares, compared to its average volume of 2,366,833. BioMarin Pharmaceutical has a 52-week low of $49.26 and a 52-week high of $70.98. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The stock has a market cap of $10.58 billion, a price-to-earnings ratio of 147.78, a P/E/G ratio of 0.39 and a beta of 0.22. The company’s 50 day moving average price is $63.01 and its 200 day moving average price is $58.66.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The business’s revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, research analysts anticipate that BioMarin Pharmaceutical will post 4.10 EPS for the current year.

Institutional Trading of BioMarin Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in BMRN. Parkside Financial Bank & Trust grew its stake in shares of BioMarin Pharmaceutical by 70.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 187 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $39,000. Keating Financial Advisory Services Inc. acquired a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $56,000. Wick Capital Partners LLC purchased a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth approximately $73,000. Finally, Parallel Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 33.9% during the first quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 448 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.